Based on clinical trials, mTOR inhibition in combination with an endocrine therapy is a new therapeutic strategy for women with advanced breast cancer who have previously relapsed on a non-steroidal aromatase inhibitor (49). The gene discussed is CYP19A1; the disease is breast cancer.